JP2000500013A - プソイドタイプのレトロウイルスを産生する安定パッケージング細胞株 - Google Patents
プソイドタイプのレトロウイルスを産生する安定パッケージング細胞株Info
- Publication number
- JP2000500013A JP2000500013A JP9518303A JP51830397A JP2000500013A JP 2000500013 A JP2000500013 A JP 2000500013A JP 9518303 A JP9518303 A JP 9518303A JP 51830397 A JP51830397 A JP 51830397A JP 2000500013 A JP2000500013 A JP 2000500013A
- Authority
- JP
- Japan
- Prior art keywords
- retroviral
- retrovirus
- expression
- cells
- cell line
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241001430294 unidentified retrovirus Species 0.000 title claims abstract description 149
- 238000004806 packaging method and process Methods 0.000 title claims abstract description 131
- 210000004027 cell Anatomy 0.000 claims abstract description 320
- 230000001177 retroviral effect Effects 0.000 claims abstract description 223
- 230000014509 gene expression Effects 0.000 claims abstract description 157
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 107
- 239000002299 complementary DNA Substances 0.000 claims abstract description 105
- 108010027225 gag-pol Fusion Proteins Proteins 0.000 claims abstract description 84
- 239000013598 vector Substances 0.000 claims abstract description 79
- 210000004962 mammalian cell Anatomy 0.000 claims abstract description 66
- 238000000034 method Methods 0.000 claims abstract description 54
- 230000001939 inductive effect Effects 0.000 claims abstract description 47
- 241000701022 Cytomegalovirus Species 0.000 claims abstract description 41
- 238000004519 manufacturing process Methods 0.000 claims abstract description 35
- 101150047047 gag-pol gene Proteins 0.000 claims abstract description 27
- 238000010367 cloning Methods 0.000 claims abstract description 21
- 241000701024 Human betaherpesvirus 5 Species 0.000 claims abstract description 10
- 238000003780 insertion Methods 0.000 claims abstract description 8
- 230000037431 insertion Effects 0.000 claims abstract description 8
- 108700001624 vesicular stomatitis virus G Proteins 0.000 claims description 83
- 241000700605 Viruses Species 0.000 claims description 68
- 239000002245 particle Substances 0.000 claims description 61
- 102000004169 proteins and genes Human genes 0.000 claims description 45
- 239000004098 Tetracycline Substances 0.000 claims description 22
- 235000019364 tetracycline Nutrition 0.000 claims description 22
- 150000003522 tetracyclines Chemical class 0.000 claims description 22
- 241000713869 Moloney murine leukemia virus Species 0.000 claims description 21
- 229960002180 tetracycline Drugs 0.000 claims description 21
- 229930101283 tetracycline Natural products 0.000 claims description 21
- 101710091045 Envelope protein Proteins 0.000 claims description 16
- 101710188315 Protein X Proteins 0.000 claims description 16
- 241001529936 Murinae Species 0.000 claims description 15
- 230000003612 virological effect Effects 0.000 claims description 13
- 239000013612 plasmid Substances 0.000 claims description 9
- 238000012546 transfer Methods 0.000 claims description 9
- 108020004414 DNA Proteins 0.000 claims description 6
- 238000012216 screening Methods 0.000 claims description 5
- 208000032839 leukemia Diseases 0.000 claims description 3
- 239000002773 nucleotide Substances 0.000 claims description 3
- 125000003729 nucleotide group Chemical group 0.000 claims description 3
- 102100021696 Syncytin-1 Human genes 0.000 claims 4
- 208000025113 myeloid leukemia Diseases 0.000 claims 1
- 210000002845 virion Anatomy 0.000 abstract description 19
- 238000001400 expression cloning Methods 0.000 abstract description 16
- 230000007812 deficiency Effects 0.000 abstract description 5
- 239000012634 fragment Substances 0.000 description 25
- 210000005260 human cell Anatomy 0.000 description 19
- 102100034349 Integrase Human genes 0.000 description 15
- 239000002609 medium Substances 0.000 description 13
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 239000001963 growth medium Substances 0.000 description 11
- 230000035772 mutation Effects 0.000 description 10
- 238000001890 transfection Methods 0.000 description 9
- 238000003146 transient transfection Methods 0.000 description 7
- 108090000288 Glycoproteins Proteins 0.000 description 6
- 238000010276 construction Methods 0.000 description 6
- 238000012217 deletion Methods 0.000 description 6
- 230000037430 deletion Effects 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 108091027963 non-coding RNA Proteins 0.000 description 6
- 102000042567 non-coding RNA Human genes 0.000 description 6
- 102000003886 Glycoproteins Human genes 0.000 description 5
- 101000899111 Homo sapiens Hemoglobin subunit beta Proteins 0.000 description 5
- 108091023040 Transcription factor Proteins 0.000 description 5
- 102000040945 Transcription factor Human genes 0.000 description 5
- 239000013604 expression vector Substances 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 239000011550 stock solution Substances 0.000 description 5
- 102100026189 Beta-galactosidase Human genes 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 108010005774 beta-Galactosidase Proteins 0.000 description 4
- 239000013599 cloning vector Substances 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 230000001566 pro-viral effect Effects 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- 102000000588 Interleukin-2 Human genes 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 239000012124 Opti-MEM Substances 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- 241000711975 Vesicular stomatitis virus Species 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 108700004029 pol Genes Proteins 0.000 description 3
- 101150088264 pol gene Proteins 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 230000001052 transient effect Effects 0.000 description 3
- 240000006409 Acacia auriculiformis Species 0.000 description 2
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 2
- 206010010099 Combined immunodeficiency Diseases 0.000 description 2
- 101100364969 Dictyostelium discoideum scai gene Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 2
- 241000713862 Moloney murine sarcoma virus Species 0.000 description 2
- 101100364971 Mus musculus Scai gene Proteins 0.000 description 2
- 208000009642 Severe combined immunodeficiency due to adenosine deaminase deficiency Diseases 0.000 description 2
- 235000003205 Smilax rotundifolia Nutrition 0.000 description 2
- 240000009022 Smilax rotundifolia Species 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 208000036556 autosomal recessive T cell-negative B cell-negative NK cell-negative due to adenosine deaminase deficiency severe combined immunodeficiency Diseases 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 229910052804 chromium Inorganic materials 0.000 description 2
- 239000011651 chromium Substances 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 230000004129 fatty acid metabolism Effects 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 108700004026 gag Genes Proteins 0.000 description 2
- 101150098622 gag gene Proteins 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000011813 knockout mouse model Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 238000002976 reverse transcriptase assay Methods 0.000 description 2
- 239000004576 sand Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000010474 transient expression Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- NWXMGUDVXFXRIG-NAOJVREFSA-N (4s,4as,5as,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2C(O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O NWXMGUDVXFXRIG-NAOJVREFSA-N 0.000 description 1
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 108091028026 C-DNA Proteins 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 102000016736 Cyclin Human genes 0.000 description 1
- 108050006400 Cyclin Proteins 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 101150082239 G gene Proteins 0.000 description 1
- 208000015872 Gaucher disease Diseases 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 102000004547 Glucosylceramidase Human genes 0.000 description 1
- 108010017544 Glucosylceramidase Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 description 1
- 101000920686 Homo sapiens Erythropoietin Proteins 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
- 241000282620 Hylobates sp. Species 0.000 description 1
- 208000000563 Hyperlipoproteinemia Type II Diseases 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 108010001831 LDL receptors Proteins 0.000 description 1
- 108010054278 Lac Repressors Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 101000756643 Rattus norvegicus Actin, cytoplasmic 1 Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 208000005074 Retroviridae Infections Diseases 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 241000711517 Torovirus Species 0.000 description 1
- 206010045261 Type IIa hyperlipidaemia Diseases 0.000 description 1
- 101150054156 VG gene Proteins 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 238000011965 cell line development Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002038 chemiluminescence detection Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 201000001386 familial hypercholesterolemia Diseases 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 108060003196 globin Proteins 0.000 description 1
- 102000018146 globin Human genes 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010376 human cloning Methods 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000007422 luminescence assay Methods 0.000 description 1
- 230000034217 membrane fusion Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 108010089520 pol Gene Products Proteins 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- -1 potassium ferricyanide Chemical compound 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000003660 reticulum Anatomy 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000037432 silent mutation Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13051—Methods of production or purification of viral material
- C12N2740/13052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55515595A | 1995-11-08 | 1995-11-08 | |
| US08/555,155 | 1995-11-08 | ||
| US65105096A | 1996-05-21 | 1996-05-21 | |
| US08/651,050 | 1996-05-21 | ||
| PCT/US1996/017807 WO1997017457A2 (en) | 1995-11-08 | 1996-11-07 | Stable packaging cell line producing pseudotyped retroviruses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2000500013A true JP2000500013A (ja) | 2000-01-11 |
Family
ID=27070812
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP9518303A Pending JP2000500013A (ja) | 1995-11-08 | 1996-11-07 | プソイドタイプのレトロウイルスを産生する安定パッケージング細胞株 |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP0859856A2 (de) |
| JP (1) | JP2000500013A (de) |
| CA (1) | CA2237000A1 (de) |
| WO (1) | WO1997017457A2 (de) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6852703B1 (en) | 1997-06-04 | 2005-02-08 | Oxford Biomedica (Uk) Limited | Tumor targeted vector |
| WO1999020742A2 (en) * | 1997-10-20 | 1999-04-29 | Universita' Degli Studi Di Padova | A packaging cell line producing siv-pseudotyped mlv |
| CA2328404C (en) | 1998-05-13 | 2007-07-24 | Genetix Pharmaceuticals, Inc. | Novel lentiviral packaging cells |
| GB0009760D0 (en) | 2000-04-19 | 2000-06-07 | Oxford Biomedica Ltd | Method |
| GB0024550D0 (de) | 2000-10-06 | 2000-11-22 | Oxford Biomedica Ltd | |
| CA2344208A1 (en) | 2001-04-30 | 2002-10-30 | Oxford Biomedica (Uk) Limited | Method |
| AUPR518501A0 (en) | 2001-05-22 | 2001-06-14 | Unisearch Limited | Yin yang-1 |
| SI1504108T1 (sl) | 2002-02-01 | 2013-07-31 | Oxford Biomedica (Uk) Limited | Lentiviralni vektor |
| CA2606287A1 (en) | 2005-05-13 | 2006-11-16 | Oxford Biomedica (Uk) Limited | Peptide |
| WO2010085660A2 (en) | 2009-01-23 | 2010-07-29 | Roger Williams Hospital | Viral vectors encoding multiple highly homologous non-viral polypeptides and the use of same |
| US20120310140A1 (en) | 2010-12-01 | 2012-12-06 | Spinal Modulation, Inc. | Directed delivery of agents to neural anatomy |
| GB201318804D0 (en) | 2013-10-24 | 2013-12-11 | Adaptimmune Ltd | Vectors for transgene expression |
| DE102020111571A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| DE102020106710A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| WO2025240518A1 (en) | 2024-05-14 | 2025-11-20 | Dispatch Biotherapeutics, Inc. | Modified lentiviral transfer plasmids |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5512421A (en) * | 1991-02-19 | 1996-04-30 | The Regents Of The University Of California | Generation, concentration and efficient transfer of VSV-G pseudotyped retroviral vectors |
| EP0769968B1 (de) * | 1994-08-17 | 2005-01-26 | Genetic Therapy, Inc. | Retrovirale vektoren, die von gegen lyse durch menschliches serum resistenten produktionszellinien produziert werden |
| US5750396A (en) * | 1995-05-08 | 1998-05-12 | St. Judes Children's Research Hospital | Stable virus packaging cell lines |
-
1996
- 1996-11-07 CA CA 2237000 patent/CA2237000A1/en not_active Abandoned
- 1996-11-07 WO PCT/US1996/017807 patent/WO1997017457A2/en not_active Ceased
- 1996-11-07 JP JP9518303A patent/JP2000500013A/ja active Pending
- 1996-11-07 EP EP96942729A patent/EP0859856A2/de not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CA2237000A1 (en) | 1997-05-15 |
| WO1997017457A2 (en) | 1997-05-15 |
| WO1997017457A3 (en) | 1997-09-12 |
| EP0859856A2 (de) | 1998-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5591624A (en) | Retroviral packaging cell lines | |
| US8034620B2 (en) | Lentiviral packaging cells and uses therefor | |
| Ory et al. | A stable human-derived packaging cell line for production of high titer retrovirus/vesicular stomatitis virus G pseudotypes. | |
| US5817491A (en) | VSV G pseusdotyped retroviral vectors | |
| US5910434A (en) | Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant | |
| JP3547129B2 (ja) | 変更宿主域を有するウィルス粒子 | |
| JP4092278B2 (ja) | パッケージング細胞 | |
| US7070994B2 (en) | Packaging cells | |
| SA518391585B1 (ar) | طريقة تحوير عابر لإنتاج فيروس عكسي | |
| JP2000500013A (ja) | プソイドタイプのレトロウイルスを産生する安定パッケージング細胞株 | |
| EP1484409B1 (de) | DNA-Konstrukt umfassend ein Medikamenten-Resistenzgen und ein fremdes Gen | |
| JPWO1998027217A1 (ja) | 遺伝子治療用レトロウイルスベクターの作製法 | |
| US6111087A (en) | Expression of a foamy virus envelope protein | |
| WO1998050538A1 (en) | Mus dunni endogenous retroviral packaging cell lines | |
| JPH09501046A (ja) | β−グロビン遺伝子およびβ−遺伝子座制御領域誘導体を導入するためのレトロウイルスベクター | |
| US5766945A (en) | 10A1 Retroviral packaging cells and uses thereof | |
| US6432709B1 (en) | Encapsidation cell lines and expression vectors for transcomplementation of defective retroviral vectors | |
| EP0511311A1 (de) | Neuartige retrovirale vektoren | |
| US20070042494A1 (en) | Heterologous retroviral packaging system | |
| AU733948B2 (en) | Expression of a modified foamy virus envelope protein | |
| EP0870050B1 (de) | Toxisches protein exprimierende viren und produktionszellinien | |
| WO2004024905A1 (en) | Recombinant human herpes simplex virus for producing lentivirus vectors | |
| JP2002515255A (ja) | 両種指向性レトロウイルスパッケージング細胞株、その生産方法及びその使用 | |
| AU1972401A (en) | Production of high titer helper-free retroviruses by transient transfection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040302 |
|
| A601 | Written request for extension of time |
Effective date: 20040601 Free format text: JAPANESE INTERMEDIATE CODE: A601 |
|
| A602 | Written permission of extension of time |
Effective date: 20040712 Free format text: JAPANESE INTERMEDIATE CODE: A602 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040902 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050607 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20050906 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20051017 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20051207 |
|
| A02 | Decision of refusal |
Effective date: 20060411 Free format text: JAPANESE INTERMEDIATE CODE: A02 |